Long non-coding RNA (lncRNA) is a type of non-coding RNA with length of nucleotides > 200 bp. Increasing evidences show that lncRNA breast cancer antiestrogen resistance 4 (BCAR4) plays an important role in the occurrence and development of various human cancers. It is found that BCAR4 is highly expressed in diverse tumor tissues and cells, and the high expression of BCAR4 is usually associated with poor prognosis. BCAR4 is considered as an oncogene in human cancers. By competing endogenous RNA (ceRNA) mechanism and regulating different signaling pathways, BCAR4 participates in the proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), metastasis and tumorigenesis of different cancers. In addition, overexpression of BCAR4 promotes drug resistance of tumor cells. Therefore, BCAR4 is a promising biomarker for cancer diagnosis and prognosis, and it is a potential target for cancer therapy. This paper reviews studies focusing on the relationship between BCAR4 and cancers in recent years and aims to summarize the effect and mechanism of BCAR4 in human cancers.

长链非编码 RNA (lncRNA) 是一类核苷酸长度 > 200 bp 的非编码 RNA。越来越多的证据表明，lncRNA乳腺癌抗雌激素抵抗4（BCAR4）在多种人类癌症的发生和发展中起着重要作用。发现BCAR4在多种肿瘤组织和细胞中高表达，BCAR4高表达通常与预后不良有关。BCAR4 被认为是人类癌症中的致癌基因。BCAR4通过竞争内源性RNA（ceRNA）机制和调节不同的信号通路，参与不同癌症的增殖、凋亡、迁移、侵袭、上皮间质转化（EMT）、转移和肿瘤发生。此外，BCAR4的过表达促进了肿瘤细胞的耐药性。所以，BCAR4是一种很有前景的癌症诊断和预后生物标志物，也是癌症治疗的潜在靶点。本文综述了近年来围绕BCAR4与癌症关系的研究，旨在总结BCAR4在人类癌症中的作用和机制。